Senti Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2023 | 4,569,900 | 1 | 311,256 | — | (244,344) | 66,913 |
| Vesting of early exercise of common stock options | 1,266 | — | 34 | — | — | 34 |
| Stock-based compensation expense | — | — | 1,258 | — | — | 1,258 |
| Net loss | — | — | — | — | (12,111) | (12,111) |
| Balance as of March 31, 2024 | 4,571,166 | 1 | 312,548 | — | (256,455) | 56,094 |
| Vesting of early exercise of common stock options | 1,266 | — | 33 | — | — | 33 |
| Stock-based compensation expense | — | — | (776) | — | — | (776) |
| Unrealized loss on investments | — | — | — | — | — | — |
| Net loss | — | — | — | — | (11,203) | (11,203) |
| Balance as of June 30, 2024 | 4,572,432 | $1 | $311,805 | $— | $(267,658) | $44,148 |
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of December 31, 2022 | 4,406,137 | $— | $300,548 | $1 | $(173,286) | $127,263 | |||||
| Vesting of early exercise of common stock options | 1,266 | — | 34 | — | — | 34 | |||||
| Stock-based compensation expense | — | 3,763 | — | — | 3,763 | ||||||
| Unrealized gain on investments | — | — | — | 2 | — | 2 | |||||
| Net loss | — | — | — | — | (18,722) | (18,722) | |||||
| Balance as of March 31, 2023 | 4,407,403 | — | 304,345 | 3 | (192,008) | 112,340 | |||||
| Vesting of early exercise of common stock options | 1,266 | — | 34 | — | — | 34 | |||||
| Issuance of common stock under Employee Stock Purchase Plan (ESPP) | 37,715 | — | 308 | — | — | 308 | |||||
| Stock-based compensation expense | — | — | 3,434 | — | — | 3,434 | |||||
| Unrealized loss on investments | — | — | — | (3) | — | (3) | |||||
| Net loss | — | — | — | — | (18,697) | (18,697) | |||||
| Balance as of June 30, 2023 | 4,446,384 | $— | $308,121 | $— | $(210,705) | $97,416 | |||||
All periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on July 17, 2024. Refer to Note 2. Summary of Significant Accounting Policies for further information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.